DE790059T1 - Vorrichtung zur behandlung von auto-immunkrankheiten und verfahren zur behandlung - Google Patents

Vorrichtung zur behandlung von auto-immunkrankheiten und verfahren zur behandlung

Info

Publication number
DE790059T1
DE790059T1 DE0790059T DE95913445T DE790059T1 DE 790059 T1 DE790059 T1 DE 790059T1 DE 0790059 T DE0790059 T DE 0790059T DE 95913445 T DE95913445 T DE 95913445T DE 790059 T1 DE790059 T1 DE 790059T1
Authority
DE
Germany
Prior art keywords
treating
glycoprotein
trophoblastic
autoimmune diseases
immune diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE0790059T
Other languages
English (en)
Inventor
Khallar Abdumuslimovich Moscow 115320 Alikhanov
Ivan Nikolaevich Moscow 115492 Golovistikov
Leonid Yazonovich Tbilici 380019 Kacharava
Jury Semyonovich Moscow 117343 Tatarinov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE790059T1 publication Critical patent/DE790059T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • External Artificial Organs (AREA)

Claims (4)

  1. DE/EP O 780
    PATENTANSPRÜCHE
    111 / E_ LJ EI &iacgr; M ! i 6 a . a '
    L- Eine Verwendung von trophoblastischem ß-1-Glycoprotein (TBG) als Behandlungsmittel für Autoimmunkrankheiten.
  2. 2.- Ein Behandlungsverfahren von Autoimmunkrankheiten umfassend die Eingabe einer immunkorrigierenden Zubereitung, gekennzeichnet dadurch, daß der Immunstatus voruntersucht ist, und falls ein Suppressordefizit vorgefunden wird, als immunkorrigierende Zubereitung trophoblastisches ß-1-Glycoprotein in Dosen von 3 bis 120 &mgr;g pro ml Blut gegeben wird.
  3. 3.- Das Verfaliren gemäß Anspruch 2, gekennzeichnet dadurch, daß das trophoblastische ß-1-Glycoprotein parenteral eingegeben wird.
  4. 4.- Das Verfahren gemäß Anspruch 2. gekennzeichnet dadurch, daß das trophoblastische ß-1-Glycoprotein, in einer Konzentration von 60 &mgr;§/&pgr;&igr;1 mit aus peripherem Blut isolierten autoimmunen Zellen kultiviert wird und intravenös eingegeben wird.
DE0790059T 1994-03-18 1995-03-16 Vorrichtung zur behandlung von auto-immunkrankheiten und verfahren zur behandlung Pending DE790059T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU9494008169A RU2056852C1 (ru) 1994-03-18 1994-03-18 Средство для лечения аутоиммунных заболеваний с иммунодефицитом супрессоров и способ лечения аутоиммунных заболеваний
PCT/RU1995/000047 WO1995025531A1 (fr) 1994-03-18 1995-03-16 Agent therapeutique contre les maladies auto-immunes et mode de traitement

Publications (1)

Publication Number Publication Date
DE790059T1 true DE790059T1 (de) 1998-03-12

Family

ID=20153349

Family Applications (2)

Application Number Title Priority Date Filing Date
DE0790059T Pending DE790059T1 (de) 1994-03-18 1995-03-16 Vorrichtung zur behandlung von auto-immunkrankheiten und verfahren zur behandlung
DE69532611T Expired - Lifetime DE69532611D1 (de) 1994-03-18 1995-03-16 Mittel zur behandlung von autoimmunkrankheiten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69532611T Expired - Lifetime DE69532611D1 (de) 1994-03-18 1995-03-16 Mittel zur behandlung von autoimmunkrankheiten

Country Status (22)

Country Link
US (1) US6150326A (de)
EP (1) EP0790059B1 (de)
JP (1) JPH09510473A (de)
KR (1) KR100382252B1 (de)
CN (1) CN1146156A (de)
AT (1) ATE260111T1 (de)
AU (1) AU699896B2 (de)
BG (1) BG62759B1 (de)
CA (1) CA2185892A1 (de)
CZ (1) CZ285856B6 (de)
DE (2) DE790059T1 (de)
ES (1) ES2107980T1 (de)
FI (1) FI963671A (de)
GE (1) GEP20012377B (de)
GR (1) GR980300023T1 (de)
HU (1) HUT75720A (de)
NO (1) NO963911L (de)
PL (1) PL179765B1 (de)
RU (1) RU2056852C1 (de)
SK (1) SK281948B6 (de)
UA (1) UA26939C2 (de)
WO (1) WO1995025531A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0030729D0 (en) * 2000-12-16 2001-01-31 Univ Nottingham Substituted-4-Quinolones
CA2501940A1 (en) * 2002-10-09 2004-04-22 Tolerrx, Inc. Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use
RU2303995C1 (ru) * 2006-04-28 2007-08-10 Халлар Абдумуслимович Алиханов Средство, обладающее иммунорегуляторным свойством и его применение для лечения аутоиммунных заболеваний

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2862449D1 (en) * 1977-08-22 1984-11-22 Nat Res Dev Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them
JPS61186322A (ja) * 1985-02-13 1986-08-20 Nippon Univ 免疾調節剤
IT1188646B (it) * 1986-04-09 1988-01-20 Ellem Ind Farmaceutica Tripeptide ad attivita' immunostimolante
US4803072A (en) * 1986-09-10 1989-02-07 Smithkline Beckman Corporation Immunomodulation
FR2609632B1 (fr) * 1987-01-21 1991-03-29 Shelly Marc Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage
US5169835A (en) * 1989-01-18 1992-12-08 Oklahoma Medical Research Foundation Pregancy specific proteins applications
FR2650183A1 (fr) * 1989-07-25 1991-02-01 Pasteur Institut Proteines immunostimulantes, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et application de ces produits a des fins therapeutiques et de diagnostic
US5118669A (en) * 1989-09-20 1992-06-02 Hitachi Chemical Co., Ltd. Peptides and intermediates therefor useful as antiallergic agents, vasodilators and immunoregulators
US5559097A (en) * 1990-01-12 1996-09-24 Idaho Research Foundation, Inc. Use of a pregnancy specific protein as an immunosuppressive
RU1836957C (ru) * 1990-03-25 1993-08-30 2-й Московский государственный медицинский институт им.Н.И.Пирогова Способ получени трофобластического бета @ -гликопротеина
GB2251186A (en) * 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease

Also Published As

Publication number Publication date
SK118796A3 (en) 1997-06-04
DE69532611D1 (de) 2004-04-01
AU2087495A (en) 1995-10-09
CA2185892A1 (en) 1995-09-28
EP0790059B1 (de) 2004-02-25
CZ274796A3 (en) 1997-06-11
UA26939C2 (uk) 1999-12-29
RU2056852C1 (ru) 1996-03-27
PL179765B1 (pl) 2000-10-31
ATE260111T1 (de) 2004-03-15
FI963671A (fi) 1996-11-14
HU9602558D0 (en) 1996-11-28
PL316311A1 (en) 1997-01-06
NO963911L (no) 1996-11-08
BG100921A (en) 1997-12-30
AU699896B2 (en) 1998-12-17
EP0790059A1 (de) 1997-08-20
CN1146156A (zh) 1997-03-26
ES2107980T1 (es) 1997-12-16
JPH09510473A (ja) 1997-10-21
CZ285856B6 (cs) 1999-11-17
SK281948B6 (sk) 2001-09-11
GR980300023T1 (en) 1998-04-30
FI963671A0 (fi) 1996-09-17
BG62759B1 (bg) 2000-07-31
EP0790059A4 (de) 2000-11-02
KR970701557A (ko) 1997-04-12
US6150326A (en) 2000-11-21
WO1995025531A1 (fr) 1995-09-28
GEP20012377B (en) 2001-03-25
NO963911D0 (no) 1996-09-18
KR100382252B1 (ko) 2003-07-07
HUT75720A (en) 1997-05-28

Similar Documents

Publication Publication Date Title
Shapira et al. Superoxide formation and chemiluminescence of peripheral polymorphonuclear leukocytes in rapidly progressive periodontitis patients
NZ235131A (en) Antibodies and proteins for inhibiting adherence of lymphocytes to endothelial cells or for preventing lymphocyte migration into tissues; pharmaceutical compositions
FEDER A heme-peptide as an ultrastructural tracer
DE69433933D1 (de) Verfahren und vorrichtung zur einkapselung biologisch aktiver substanzen in zellen
ATE169820T1 (de) Verwendung eines bakteriziden/die permeabilität erhöhenden proteins oder von biologisch aktiven analogen davon zur herstellung eines arzneimittels zur behandlung von endotoxin- assoziierten storungen
Scolding et al. Oligodendrocyte susceptibility to injury by T-cell perforin.
IL96434A0 (en) Cascade polymers,processes for the preparation thereof and pharmaceutical compositions containing the same
ATE64551T1 (de) Verfahren zur herstellung von platingruppenmetallen enthaltenden katalysatoren und deren verwendungen.
DE58903791D1 (de) Peptidderivate, verfahren zu ihrer herstellung und ihre verwendung.
EP1074615A1 (de) Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie
DE69020979D1 (de) Neue Arginin-Deiminase, Verfahren zu ihrer Herstellung und ein Antikrebsmittel, das dieses Enzym als wirksamen Bestandteil enthält.
DE59005996D1 (de) Verfahren zur Herstellung von Titanocenen mit o,o'- Difluorarylliganden.
DE790059T1 (de) Vorrichtung zur behandlung von auto-immunkrankheiten und verfahren zur behandlung
Wagemaker et al. Erythropoietin‐independent regeneration of erythroid progenitor cells following multiple injections of hydroxyurea
Lotem et al. Genetic dissociation of different cellular effects of interferon on myeloid leukemic cells
Pepper et al. The different forms of antithrombin III in serum
Brunner et al. Phenylketonuria and sustained attention: The continuous performance test.
Steel et al. Non-random chromosome gains in human lymphoblastoid cell lines
Ozer Jr et al. The response of rabbit lymphocytes to mitogens and alloantigens: evidence for T cell heterogeneity
Mishell et al. Prevention of the in vitro myelosuppressive effects of glucocorticosteroids by interleukin 1 (IL 1).
Golemboski et al. Dynamics of avian inflammatory response to cross-linked dextran: changes in avian blood leukocyte populations
Birgegård Erythropoiesis and inflammation
EP0186476A3 (de) Diagnosepackung und Verfahren zur Prüfung von Blutbestandteilen
Sorg Modulation of macrophage functions by lymphokines
DE3888539D1 (de) Verfahren zur herstellung von kompositen auf chrom basierten verbundbeschichtungen.